Tofacitinib, an oral Janus kinase inhibitor, is an effective treatment for rheumatoid arthritis. Adverse effects are generally mild and include cytopenias and hyperlipidaemia. Opportunistic infections such as herpes zoster may occur with tofacitinib.
Bibliographical noteExcept where otherwise noted, all articles published in Australian Prescriber can be used under the CC BY-NC-ND licence.
- Molecular targeted therapy
- rheumatoid arthritis